Cyteir Therapeutics
Financial ratios & Valuation

Forward Multiples (2025 – 2025)

2025
Price/Earnings ratio
N/A
Price/Sales ratio
N/A
Earnings per Share (EPS)
$-0.66

Historical Multiples (2019 – 2022)

2019 2020 2021 2022 TTM Median
Valuation Ratios
Price/Earnings ratio
-22.47-19.96-5.32-1.32-0.89-19.96
Price/Sales ratio
42.26KN/AN/AN/AN/AN/A
Price/Book Value ratio
-11.93-8.651.180.390.44-8.65
Price/Cash Flow ratio
-19.25-22.42-6.15-1.36-0.98-22.42
Price/Free Cash Flow ratio
-19.11-21.43-5.95-1.35-0.98-21.43
Price/Earnings Growth ratio
N/A-1.53-0.030.03-0.03-1.53
Dividend Yield
N/AN/AN/AN/AN/AN/A
Profitability Indicator Ratios
Gross Profit Margin
-58.61%N/AN/AN/AN/AN/A
Operating Profit Margin
-201312.5%N/AN/AN/AN/AN/A
Pretax Profit Margin
-188050%N/AN/AN/AN/AN/A
Net Profit Margin
-188050%N/AN/AN/AN/AN/A
Effective Tax Rate
N/AN/A1.13%4.57%N/A1.13%
Return on Assets
-47.95%-151.60%-21.31%-28.68%-47.17%-151.60%
Return On Equity
53.09%43.35%-22.23%-30.04%-45.27%-22.23%
Return on Capital Employed
-54.78%-197.61%-22.49%-32.56%-50.38%-197.61%
Liquidity Ratios
Current Ratio
N/AN/AN/AN/A28.07N/A
Quick Ratio
14.793.8825.7128.0727.683.88
Cash ratio
14.713.4825.2527.6827.683.48
Days of Sales Outstanding
N/AN/AN/AN/AN/AN/A
Days of Inventory outstanding
36.24K-65.51-28.95N/AN/A-65.51
Operating Cycle
36.24KN/AN/AN/AN/AN/A
Days of Payables Outstanding
17.31K1.75K1.36K299.43N/A1.36K
Cash Conversion Cycle
18.92KN/AN/AN/AN/AN/A
Debt Ratios
Debt Ratio
N/AN/AN/A0.000.04N/A
Debt Equity Ratio
N/AN/AN/A0.000.04N/A
Long-term Debt to Capitalization
N/AN/AN/AN/AN/AN/A
Total Debt to Capitalization
N/AN/AN/A0.00N/AN/A
Interest Coverage Ratio
N/AN/AN/AN/AN/AN/A
Cash Flow to Debt Ratio
N/AN/AN/A-47.84N/AN/A
Company Equity Multiplier
-1.10-0.281.041.041.04-0.28
Cash Flow Ratios
Operating Cash Flow / Sales Ratio
-2.19KN/AN/AN/AN/AN/A
Free Cash Flow / Operating Cash Flow Ratio
1.001.041.031.001.001.03
Cash Flow Coverage Ratio
N/AN/AN/A-47.84N/AN/A
Short Term Coverage Ratio
N/AN/AN/A-47.84N/AN/A
Dividend Payout Ratio
N/AN/AN/AN/AN/AN/A